Nguyen DL, Myers KS, Oluyemi E, Mullen LA, Panigrahi B, Rossi J, Ambinder EB. BI-RADS 3 Assessment on MRI: A Lesion-Based Review for Breast Radiologists.
JOURNAL OF BREAST IMAGING 2022;
4:460-473. [PMID:
36247094 PMCID:
PMC9549780 DOI:
10.1093/jbi/wbac032]
[Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Indexed: 09/15/2024]
Abstract
Unlike mammography and US, limited data exist to establish well-defined criteria for MRI findings that have a ≤2% likelihood of malignancy. Therefore, determining which findings are appropriate for a BI-RADS 3 assessment on MRI remains challenging and variable among breast radiologists. Emerging data suggest that BI-RADS 3 should be limited to baseline MRI examinations (or examinations with less than two years of prior comparisons) performed for high-risk screening and only used for masses with all of the typical morphological and kinetic features suggestive of a fibroadenoma or dominant enhancing T2 hypointense foci that is distinct from background parenchymal enhancement and without suspicious kinetics. This article presents an updated discussion of BI-RADS 3 assessment (probably benign) for breast MRI using current evidence.
Collapse